Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 12 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Jan 2019.
- 23 Aug 2018 Planned initiation date changed from 1 Aug 2018 to 1 Oct 2018.
- 13 Jul 2018 New trial record